Jacques Chatain

Co-Founder, Chairman, Managing Partner, Investor Relations and Public Relations

Bernard Daugeras

Co-Founder, Partner and Chairman of Board

Sébastien Descarpentries

Managing Partner

Philippe Granger

Software Partner and Member of Executive Board

161 past transactions

Nexthink S.A.

Series A in 2010
Nexthink is a global leader in digital experience management. The company's product allows enterprises to create highly productive digital workplaces for their employees by delivering optimal end-user experience. Through a unique combination of real-time analytics, automation and employee feedback across all endpoints, Nexthink helps IT teams meet the needs of the modern digital workplace.

Biolipox

Series C in 2005
Biolipox is a research-intense pharmaceutical company that develops treatments for inflammatory diseases. This includes widespread diseases such as asthma, COPD, rhinitis, and inflammatory and rheumatic pain. The company offers its users with current arachidonic acid research. Arachidonic acid is an endogenous substance that plays a central role in the development of inflammatory diseases. It is an established research area that empowers several drugs such as Aspirin, Naproxen, and Singulair. Biolipox is a Sweden-based company that was founded in 2000 and the company was acquired by Orexo on November 23, 2007.

Median Technologies

Post in 2014
MEDIAN Technologies develops medical imaging software and services dedicated to oncology clinical trials, cancer screening, and clinical practice. The company standardizes and automates the interpretation of medical images in oncology to optimize the diagnosis of cancer patients and the assessment of their response to therapy. The company serves two primary markets: drug development and patient care. MEDIAN Technologies has a strategic partnership with a contract research organization to offer integrated imaging services for clinical trials to biopharma sponsors worldwide, and a strategic partnership with Canon to develop new imaging technologies, and to address the patient care market. MEDIAN Technologies was founded in 2002 and is based in Sophia-Antipolis, France.

eXo Platform

Series A in 2010
eXo Platform (https://www.exoplatform.com) is an open source social collaboration platform that is highly extensible and based on open standards. With eXo you can not only build an enterprise social network, but you can also build a website, a social intranet or a community website. Hundreds of large organizations—in sectors ranging from government and financial services to telecom—use eXo products today, as do thousands of enterprises in other sectors through the company’s strategic partnership with Red Hat. eXo operates globally and has offices in the United States, France, Tunisia, Ukraine and Vietnam.

SpinX Technologies

Series B in 2005
SpinX develops and commercializes a programmable lab-on-a-chip platform for applications that ranges from drug discovery to consumer diagnostics. Its products include SpinX Lab, a system to transition from low volume microplate assays to an automated bench-top technology for assays in nanoliter volumes; and workflow, an assay preparation for a panel of enzymatic assays. Bart Van de Vyver and Piero Zucchelli founded SpinX in 2003. It has its headquarters in Geneva in Switzerland.

Drug Abuse Sciences

Venture Round in 1999
Drug Abuse Sciences develops and commercializes therapies for the treatment of alcohol and drug addictions. It offers Naltrexone Depot, a sustained-release formulation of Naltrexone for the treatment of alcohol and opiate addictions; DAS-431 for the treatment of cocaine addiction; and Buprenorphine Depot, a sustained-release formulation of buprenorphine for the treatment of heroin and various opiate addictions. Drug Abuse Sciences is based in Menlo Park, California.

Pherecydes Pharma

Venture Round in 2015
Pherecydes Pharma SA engages in the research and development of lytic bacteriophages for therapeutic and diagnostic applications with a focus on antibiotic resistance. It develops several banks of bacteriophages, including the collection of phages against Escherichia coli. The company was incorporated in 2006 and is based in Romainville, France.

Domain Therapeutics SA

Series A in 2002
Domain Therapeutics is a biopharmaceutical company located in Strasbourg, France, dedicated to the discovery and early development of small molecules targeting G-coupled Protein Receptors (GPCRs), one of the best classes of drug targets. Domain Therapeutics is using its innovative and proprietary technology platform DTect-Allâ„¢ to identify orthosteric and allosteric ligands of GPCRs, including the so called Silent Allosteric Modulators (SAMs) that represent a unique source of compounds that cannot be discovered by standard technologies. DTect-Allâ„¢ is able to address difficult GPCRs such as orphan and peptidic GPCRs.
Population Genetics Technologies creates products that accelerate large-scale population studies, through the simultaneous analysis of multiple individual genomes. Their proprietary technology replaces initial sample preparation steps for next-generation DNA sequencing, overcoming cost barriers and practical constraints that limit discovery.

Nexthink S.A.

Series B in 2016
Nexthink is a global leader in digital experience management. The company's product allows enterprises to create highly productive digital workplaces for their employees by delivering optimal end-user experience. Through a unique combination of real-time analytics, automation and employee feedback across all endpoints, Nexthink helps IT teams meet the needs of the modern digital workplace.

ConjuChem, LLC

Series B in 1999
ConjuChem, LLC, a biotechnology company, discovers and develops medicines using therapeutic peptides with an initial focus on diabetes. The company focuses on discovering and developing drugs based on Drug Affinity Complex (DAC) and Preformed Conjugate-Drug Affinity Complex (PC-DAC) technology platforms. Its DAC or PC-DAC platforms are applied to compounds to create new drugs with similar therapeutic activities and longer duration of activity in the body. The company’s product pipeline comprises CJC-1134-PC, a modified Exendin-4 analogue conjugated to recombinant human albumin for the treatment of type 2 diabetes; PC-DAC, an insulin product; and DAC: HIV conjugate for controlling HIV-1 infection. ConjuChem, LLC was incorporated in 2011 and is based in Los Angeles, California.

Domain Therapeutics SA

Series B in 2004
Domain Therapeutics is a biopharmaceutical company located in Strasbourg, France, dedicated to the discovery and early development of small molecules targeting G-coupled Protein Receptors (GPCRs), one of the best classes of drug targets. Domain Therapeutics is using its innovative and proprietary technology platform DTect-Allâ„¢ to identify orthosteric and allosteric ligands of GPCRs, including the so called Silent Allosteric Modulators (SAMs) that represent a unique source of compounds that cannot be discovered by standard technologies. DTect-Allâ„¢ is able to address difficult GPCRs such as orphan and peptidic GPCRs.

eXo Platform

Venture Round in 2014
eXo Platform (https://www.exoplatform.com) is an open source social collaboration platform that is highly extensible and based on open standards. With eXo you can not only build an enterprise social network, but you can also build a website, a social intranet or a community website. Hundreds of large organizations—in sectors ranging from government and financial services to telecom—use eXo products today, as do thousands of enterprises in other sectors through the company’s strategic partnership with Red Hat. eXo operates globally and has offices in the United States, France, Tunisia, Ukraine and Vietnam.

Hybrigenics

Series A in 2000
Hybrigenics Pharma is a bio-pharmaceutical company with a focus on research and development of new targets and therapies against cancer.Hybrigenics Pharma has stopped the development of inecalcitol, a vitamin D receptor agonist.Hybrigenics Pharma's research program investigates the action of enzymes called Deubiquitinating Enzymes (DUBs) in the recycling of onco-proteins and the potential activity of proprietary patented DUB inhibitors against various cancer indications.

Evolva Holding SA

Series B in 2009
Evolva was founded in 2004 around a distinctive, proprietary, technology platform that uses synthetic biology to create innovative small molecule drugs and other compounds. In particular their platform allows the creation of chemistries that recapitulate the themes found in natural products, but without the disadvantages of those approaches.

Catalyst Biosciences, Inc.

Venture Round in 2002
Catalyst Biosciences is a drug discovery and development company. It is creating novel catalytic biopharmaceutical products based on engineered human proteases. The mission is to establish protease therapeutics as a new therapeutic platform comparable in depth and scope to antibody pharmaceuticals. The Company is developing proteases for the treatment of a broad range of diseases with a strong focus on hemostasis and inflammation. Founded in 1997, the company is headquartered in South San Francisco, California.

Genocea Biosciences

Series E in 2013
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, to profile patient’s CD4+ and CD8+ T cell immune responses to potential target or antigen in that patient's tumor. It develops immuno-oncology programs, such as GEN-009, an adjuvanted neoantigen peptide vaccine candidate, which is in the phase I/IIa clinical trial; GEN-011, a neoantigen adoptive T cell therapy program; and GEN-010, a neoantigen vaccine program. Genocea Biosciences, Inc. was founded in 2006 and is based in Cambridge, Massachusetts.

Innovative Silicon

Series B in 2005
Innovative Silicon was founded to develop and commercialise Floating Body effect memory for SoC/MPU products used in diverse applications including handheld computers, games consoles, cellular communications devices, cameras. The company closed its first round of VC funding in 2003, completed its first 90nm megabit Z-RAM memory design in 2004 and its first 65nm designs in 2005. The company was founded in 2002 and is headquartered in Santa Clara, California with additional offices in Lausanne, Switzerland; and Yokohama, Japan.

Pharma Omnium

Series D in 2007
Pharma Omnium is a French pharmaceutical company that markets mature drugs in various therapeutic classes. The company provides nutraceutical, dermatological, and dermo-esthetic products.
At Santen, they’re innovating therapies to improve the quality of life for patients worldwide. Their single focus in ophthalmology enables us to challenge unmet needs in the field—through passionate research, successful collaboration, and clarity of commitment. With over 120 years of investigative insight, Santen remains committed to the discovery, exploration, and development of ophthalmic therapies. Now, and into the future. As a globally competitive company, Santen is often expanding to accommodate new and evolving initiatives in ophthalmic research, regulatory management, production, marketing, or distribution. Their clinical development network now spans three continents, with centers in Europe, Japan, and the United States.

Population Genetics Technologies

Venture Round in 2010
Population Genetics Technologies creates products that accelerate large-scale population studies, through the simultaneous analysis of multiple individual genomes. Their proprietary technology replaces initial sample preparation steps for next-generation DNA sequencing, overcoming cost barriers and practical constraints that limit discovery.

Median Technologies

Series B in 2004
MEDIAN Technologies develops medical imaging software and services dedicated to oncology clinical trials, cancer screening, and clinical practice. The company standardizes and automates the interpretation of medical images in oncology to optimize the diagnosis of cancer patients and the assessment of their response to therapy. The company serves two primary markets: drug development and patient care. MEDIAN Technologies has a strategic partnership with a contract research organization to offer integrated imaging services for clinical trials to biopharma sponsors worldwide, and a strategic partnership with Canon to develop new imaging technologies, and to address the patient care market. MEDIAN Technologies was founded in 2002 and is based in Sophia-Antipolis, France.

Amplitude

Series B in 2012
AMPLITUDE TECHNOLOGIES is the global expert in the science, design and manufacture of high performance laser systems for a variety of specialist applications. ln addition to systems used for fundamental physics research, the company is a leading authority in the medical research domain including radiography and cancer treatment projects. AMPLITUDE TECHNOLOGIES offers worldwide project management experience. Its comprehensive project management program provides industry-leading levels of customer support. From the first steps of the design concept, to laboratory installation, training and ongoing after-sales requirements, the Amplitude team is on-hand to provide the support the application demands. Over a decade' s experience in the Science, design and development, and support of state-of-the-art systems in the field means that every AMPLITUDE TECHNOLOGIES system is engineered to be extremely robust and reliable, offering unparalleled performance no matter what the application.

Median Technologies

Series E in 2010
MEDIAN Technologies develops medical imaging software and services dedicated to oncology clinical trials, cancer screening, and clinical practice. The company standardizes and automates the interpretation of medical images in oncology to optimize the diagnosis of cancer patients and the assessment of their response to therapy. The company serves two primary markets: drug development and patient care. MEDIAN Technologies has a strategic partnership with a contract research organization to offer integrated imaging services for clinical trials to biopharma sponsors worldwide, and a strategic partnership with Canon to develop new imaging technologies, and to address the patient care market. MEDIAN Technologies was founded in 2002 and is based in Sophia-Antipolis, France.

TxCell S.A.

Post in 2017
TxCell, a spin off of Inserm (France's National Institute for Health and Medical Research) located in the technology park of Sophia Antipolis, near Nice in southern France, is developing cell-based immuno-therapies for the treatment of severe chronic inflammatory diseases with high medical need using its unique and proprietary technology platform based on the properties of Type 1 regulatory T lymphocytes (Tr1 cells). The company has completed enrollment of a PhI/II study in refractory Crohn's disease patients and has reported first positive results. The company plans to initiate a PhIIb study in the same patient population and bring a second product candidate into a PhI/II study in refractory rheumatoid arthritis patients.

Domain Therapeutics SA

Series C in 2006
Domain Therapeutics is a biopharmaceutical company located in Strasbourg, France, dedicated to the discovery and early development of small molecules targeting G-coupled Protein Receptors (GPCRs), one of the best classes of drug targets. Domain Therapeutics is using its innovative and proprietary technology platform DTect-Allâ„¢ to identify orthosteric and allosteric ligands of GPCRs, including the so called Silent Allosteric Modulators (SAMs) that represent a unique source of compounds that cannot be discovered by standard technologies. DTect-Allâ„¢ is able to address difficult GPCRs such as orphan and peptidic GPCRs.

Genocea Biosciences

Series C in 2012
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, to profile patient’s CD4+ and CD8+ T cell immune responses to potential target or antigen in that patient's tumor. It develops immuno-oncology programs, such as GEN-009, an adjuvanted neoantigen peptide vaccine candidate, which is in the phase I/IIa clinical trial; GEN-011, a neoantigen adoptive T cell therapy program; and GEN-010, a neoantigen vaccine program. Genocea Biosciences, Inc. was founded in 2006 and is based in Cambridge, Massachusetts.

SuperSonic Imagine SA

Series A in 2006
SuperSonic Imagine SA operates as a medical technology company. It designs, develops, and markets Aixplorer, an ultrasound system. It has developed a technology that offers practitioners and patients a breakthrough in the diagnosis and follow up of breast, prostate, and thyroid cancers, as well as liver diseases. The company’s products include Aixplorer, an ultrasound system that renders images with exceptional definition, contrast, and resolution. It operates primarily in China, the United States, and France. The company was founded in 2005 and is headquartered in Aix-en-Provence, France. SuperSonic Imagine SA is a subsidiary of Hologic Hub Ltd.

EKINOPS S.A.

Series C in 2009
Ekinops is a provider of next-generation optical transport solutions for service providers and private networks. Its carrier-grade solutions leverage expertise in 10G transmission, aggregation and Forward Error Correction (FEC) to allow operators to cost-effectively increase data transport capacity over dark fiber, CWDM, DWDM, SONET/SDH, IP and SAN networks.

aveni

Series F in 2014
aveni, Inc. provides metallization technologies for damascene through silicon vias, MEMS, and other electronic applications. Its portfolio includes Electrografting (eG), a wet electrochemical-based process that enables the growth of extremely high-quality thin films of various types on conducting and semiconducting surfaces; and Chemicalgrafting (cG), which is used on non-conductive substrates. The company’s eG and cG processes are implemented on hardware platforms or run on tools ranging from wet benches to automated systems. It serves semiconductor and renewable energy companies worldwide. aveni, Inc. was formerly known as Alchimer S.A. The company was founded in 2001 and is based in Massy, France.

Bag Tech

Series C in 2006
Bag Tech develops, designs, and manufactures a variety of bags.

EKINOPS S.A.

Series B in 2007
Ekinops is a provider of next-generation optical transport solutions for service providers and private networks. Its carrier-grade solutions leverage expertise in 10G transmission, aggregation and Forward Error Correction (FEC) to allow operators to cost-effectively increase data transport capacity over dark fiber, CWDM, DWDM, SONET/SDH, IP and SAN networks.

NEMOPTIC

Series A in 1999
Nemoptic, an epaper display company, designs and manufactures superior-quality bistable liquid crystal displays (LCD) modules highly suitable for consumer and professional mobile devices.

EnobraQ

Seed Round in 2018
EnobraQ is a start-up created in 2015, from a pre-competitive research project supported by Toulouse White Biotechnology (TWB). Concerned with ecological and economic considerations, EnobraQ develops breakthrough technologies that use CO2 and target markets as diverse as nutrition, agri-food, cosmetics, pharmacology and bioplastics.
EVE is the leader in Hardware/Software Co-Verification. Nine of the top 10 semiconductor companies rely on ZeBu to verify their SOCs. With the best ROI on the market, ZeBu is also the choice of startups that need first-pass silicon success.
At Santen, they’re innovating therapies to improve the quality of life for patients worldwide. Their single focus in ophthalmology enables us to challenge unmet needs in the field—through passionate research, successful collaboration, and clarity of commitment. With over 120 years of investigative insight, Santen remains committed to the discovery, exploration, and development of ophthalmic therapies. Now, and into the future. As a globally competitive company, Santen is often expanding to accommodate new and evolving initiatives in ophthalmic research, regulatory management, production, marketing, or distribution. Their clinical development network now spans three continents, with centers in Europe, Japan, and the United States.

Innovative Silicon

Series A in 2004
Innovative Silicon was founded to develop and commercialise Floating Body effect memory for SoC/MPU products used in diverse applications including handheld computers, games consoles, cellular communications devices, cameras. The company closed its first round of VC funding in 2003, completed its first 90nm megabit Z-RAM memory design in 2004 and its first 65nm designs in 2005. The company was founded in 2002 and is headquartered in Santa Clara, California with additional offices in Lausanne, Switzerland; and Yokohama, Japan.

VitaDX International SA

Seed Round in 2017
VitaDX is a startup applying artificial intelligence to the healthcare sector, and more specifically to the early diagnosis of cancer by exploiting fluorescence imaging in favor of a first product, VisioCyt®, dedicated to the detection of cancer of the bladder. This solution will allow the diagnosis of bladder cancer from a simple urine sample to improve the performance of urinary cytology conventionally used in first intention.

Theranexus Société Anonyme

Seed Round in 2014
Theranexus société anonyme, a biopharmaceutical company, develops drug candidates for the treatment of central nervous system disorders. The company’s lead drug candidate is THN102, which is in Phase II clinical trial to treat sleep/wake disorders. It also develops THN201 for the treatment of neurocognitive disorders linked to Alzheimer's disease; and THN101 to treat neuropathic pain. The company was founded in 2013 and is based in Lyon, France.

Theradiag SA

Series B in 2003
Theradiag is a France-based company which develops and markets biological diagnostic tools. The company develops and offers product panels for diagnosing autoimmune diseases, allergies, and infectious diseases.

Gamida Cell Ltd.

Series B in 2001
Gamida Cell is dedicated to making a significant difference in the clinical practice of modern medicine by first creating, then tapping the regenerative power of therapeutic stem cells. Gamida Cell is a leader in the development of stem cell therapy technologies and products. The therapies are based on expanded populations of cord blood stem cells, for the treatment of illnesses with significant unmet clinical needs such as blood cancers, autoimmune and metabolic diseases as well as neutropenia.

IDbyME

Series B in 2012
Fashion Brand selling only fully customizable item under the MoodbyMe brand.

Neolane

Series B in 2006
Neolane, Inc. is a conversational marketing technology provider, which develops marketing automation and cross-channel campaign management software and services for business-to-business and business-to-consumer marketers. In 2012, Neolane recorded $58 million in revenue representing 40% year-over-year growth. In 2013, Neolane was named #64 on the Forbes list of America's Most Promising companies. Neolane provides the only conversational marketing technology that empowers organizations to build and sustain one-to-one lifetime dialogues, dramatically increasing revenue and marketing efficiency. Neolane has a track record of enabling its customers to adapt to new customer engagement challenges and exploit opportunities more quickly than their competition. Neolane is used by more than 400 of the world's leading companies including Alcatel Lucent, barnesandnoble.com, Orange, Sears Canada, Sephora Europe, and Sony Music.

Theraptosis

Series B in 2007
Theraptosis is a biopharmaceutical company that designs and develops various drugs for cancer and neurodegenerative diseases. It also offers research and development programs covering anti-angiogenesis, targeted tumor cell killing, auto-immunity, and neuroprotection. Theraptosis was founded in 2001 and is based in Romainville, France.

Bag Tech

Series A in 2003
Bag Tech develops, designs, and manufactures a variety of bags.

Vade Secure SASU

Venture Round in 2022
Vade Secure SASU provides email security software. The company offers services for emails, such as phishing and spear phishing, malware, and ransomware. The company’s products include Vada Secure for office 365, Isltphishing threat detection for security operations center (SOC), cloud for enterprise, and gateway for enterprise. It offers serves to sectors, including international ship and port facility security (ISPs), original equipment manufacturer (OEMs), hosting companies, and enterprises. The company was founded in 2008 and is based in Hem, France.

Pharma Omnium

Series F in 2009
Pharma Omnium is a French pharmaceutical company that markets mature drugs in various therapeutic classes. The company provides nutraceutical, dermatological, and dermo-esthetic products.

BonitaSoft

Series A in 2009
Bonitasoft fully supports digital operations and IT modernization with Bonita, an open-source and extensible platform for automation and optimization of business processes. The Bonita platform accelerates development and production with clear separation between capabilities for visual programming and for coding. Bonita integrates with existing information systems, orchestrates heterogeneous systems, and provides deep visibility into processes across the organization.

Entomed

Series B in 2000
Entomed

NEMOPTIC

Series C in 2003
Nemoptic, an epaper display company, designs and manufactures superior-quality bistable liquid crystal displays (LCD) modules highly suitable for consumer and professional mobile devices.

Convertigo S.A.

Venture Round in 2014
Convertigo is a privately held company recognized as a “pure player” in the enterprise Mobility market and the first software vendor to distribute its cloud based or on-premise Mobile Application Development Platform (MADP) as Open Source. Convertigo is delivering a secured and scalable disruptive all-in-one solution covering challenging backend enablement, optimized for mobility middle ware and rapid development tools for mobile applications. Convertigo team having high frequency interactions with largest customers and SI is 100% focus on developing platform and mobile oriented new features, industry solutions and practices. It’s disruptive technologies and industry standards’ integration since mobility early ages brings Convertigo to the edge of the Mobile Application Development Platform customers’ requirements. With more of 50.000 installations of its community edition, Convertigo technologies have a proven track record with secured and scalable implementations deployed in global fortune 500 companies in EMEA and North America as Carrefour, Morgan Stanley or BNP Paribas.

Eve.com

Venture Round in 2010
EVE offers massively multiplayer online roleplaying games. The company’s portfolio includes Eve Online, Eve Valkyrie, Gunjack, Dust 514, and Eve Universe.

Median Technologies

Series D in 2007
MEDIAN Technologies develops medical imaging software and services dedicated to oncology clinical trials, cancer screening, and clinical practice. The company standardizes and automates the interpretation of medical images in oncology to optimize the diagnosis of cancer patients and the assessment of their response to therapy. The company serves two primary markets: drug development and patient care. MEDIAN Technologies has a strategic partnership with a contract research organization to offer integrated imaging services for clinical trials to biopharma sponsors worldwide, and a strategic partnership with Canon to develop new imaging technologies, and to address the patient care market. MEDIAN Technologies was founded in 2002 and is based in Sophia-Antipolis, France.
At Santen, they’re innovating therapies to improve the quality of life for patients worldwide. Their single focus in ophthalmology enables us to challenge unmet needs in the field—through passionate research, successful collaboration, and clarity of commitment. With over 120 years of investigative insight, Santen remains committed to the discovery, exploration, and development of ophthalmic therapies. Now, and into the future. As a globally competitive company, Santen is often expanding to accommodate new and evolving initiatives in ophthalmic research, regulatory management, production, marketing, or distribution. Their clinical development network now spans three continents, with centers in Europe, Japan, and the United States.

Oxand S.A.S

Venture Round in 2004
Oxand is an international consulting and solutions provider with proven capabilities, knowledge and tools for capital intensive assets. As an independent company, they deliver risk-informed decision support information that improves returns across the life cycle of their clients’ assets. Their worldwide clients are investors, owners, contractors and managers in Energy (Nuclear, Oil & Gas, Renewables), Transport (Railways, Roads & Waterways) and Public/Private Properties (Public Infrastructures, Private & Industrial assets). Enhancing their clients’ reputations by supporting better decisions, with more than 1,150 billion Euros worth of analysed assets, they have experience that includes optimising the life cycle decisions and reducing costs by 10 to 30%; making possible life extension versus renewals; and reducing costly delays of large projects. Their solutions, supported by their Simeo™ technologies and data libraries, are fully compliant with best standards (as ISO 55000, ISO 31000, ISO 15288, NEC3…). They deliver tailored consultancy, training and IT solutions.

Median Technologies

Series C in 2006
MEDIAN Technologies develops medical imaging software and services dedicated to oncology clinical trials, cancer screening, and clinical practice. The company standardizes and automates the interpretation of medical images in oncology to optimize the diagnosis of cancer patients and the assessment of their response to therapy. The company serves two primary markets: drug development and patient care. MEDIAN Technologies has a strategic partnership with a contract research organization to offer integrated imaging services for clinical trials to biopharma sponsors worldwide, and a strategic partnership with Canon to develop new imaging technologies, and to address the patient care market. MEDIAN Technologies was founded in 2002 and is based in Sophia-Antipolis, France.

Implanet

Series D in 2011
Implanet S.A., together with its subsidiaries, designs, manufactures, and sells implants for orthopedic surgery in France, the United States, Brazil, and internationally. The company offers spinal, arthroscopy, and knee products. Its products include Jazz, Jazz Passer, Jazz Cap SP, Jazz Lock, Jazz Claw, Jazz Standalone, Jazz Frame, and Jazz Screw systems for posterior fixation. The company also offers knee prostheses, such as Madison for conventional surgical techniques. Implanet S.A. was founded in 2006 and is based in Martillac, France.
At Santen, they’re innovating therapies to improve the quality of life for patients worldwide. Their single focus in ophthalmology enables us to challenge unmet needs in the field—through passionate research, successful collaboration, and clarity of commitment. With over 120 years of investigative insight, Santen remains committed to the discovery, exploration, and development of ophthalmic therapies. Now, and into the future. As a globally competitive company, Santen is often expanding to accommodate new and evolving initiatives in ophthalmic research, regulatory management, production, marketing, or distribution. Their clinical development network now spans three continents, with centers in Europe, Japan, and the United States.

Implanet

Series B in 2009
Implanet S.A., together with its subsidiaries, designs, manufactures, and sells implants for orthopedic surgery in France, the United States, Brazil, and internationally. The company offers spinal, arthroscopy, and knee products. Its products include Jazz, Jazz Passer, Jazz Cap SP, Jazz Lock, Jazz Claw, Jazz Standalone, Jazz Frame, and Jazz Screw systems for posterior fixation. The company also offers knee prostheses, such as Madison for conventional surgical techniques. Implanet S.A. was founded in 2006 and is based in Martillac, France.

Innate Pharma

Series B in 2002
Innate Pharma S.A. is a biopharmaceutical company developing first-in-class immunotherapy drug candidates for cancer and inflammatory diseases. The Company specializes in the development of novel monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Its innovative approaches have led to licensing agreements with Novo Nordisk A/S and Bristol-Myers Squibb.

Nexthink S.A.

Corporate Round in 2014
Nexthink is a global leader in digital experience management. The company's product allows enterprises to create highly productive digital workplaces for their employees by delivering optimal end-user experience. Through a unique combination of real-time analytics, automation and employee feedback across all endpoints, Nexthink helps IT teams meet the needs of the modern digital workplace.

Stantum

Series B in 2009
Stantum, Inc. designs and manufactures multitouch surface controllers. Its products include Lemur, which is a control surface for audio and media applications; and DEXTER, a laptop sized control surface, which is used for controlling digital audio workstations. The company’s products are used by musicians, composers, discjockies, media artists, researchers, and developers. It offers its products through distributors and retailers internationally. The company was formerly known as JazzMutant SAS and changed its name in 2007. Stantum, Inc. was founded in 2002 and is based in Bordeaux, France with a liaison office in Tokyo, Japan.

Aquarelle

Series B in 2000
Aquarelle operates as an online florist. It offers scented seasonal bouquets for birthdays, births, weddings, and other occasions; indoor and outdoor decorations for gardens, terraces, patios, and others; and flowers, chocolates, confectionery, fruits or woodland berries, and fragrance compositions. The company operates stores in Paris and Rennes, France. It delivers products to customers in France, the United States, the United Kingdom, Canada, Australia, Ireland, India, and internationally. Aquarelle was founded in 1987 and is based in Paris, France.

Aquarelle

Series A in 1999
Aquarelle operates as an online florist. It offers scented seasonal bouquets for birthdays, births, weddings, and other occasions; indoor and outdoor decorations for gardens, terraces, patios, and others; and flowers, chocolates, confectionery, fruits or woodland berries, and fragrance compositions. The company operates stores in Paris and Rennes, France. It delivers products to customers in France, the United States, the United Kingdom, Canada, Australia, Ireland, India, and internationally. Aquarelle was founded in 1987 and is based in Paris, France.

SuperSonic Imagine SA

Series C in 2010
SuperSonic Imagine SA operates as a medical technology company. It designs, develops, and markets Aixplorer, an ultrasound system. It has developed a technology that offers practitioners and patients a breakthrough in the diagnosis and follow up of breast, prostate, and thyroid cancers, as well as liver diseases. The company’s products include Aixplorer, an ultrasound system that renders images with exceptional definition, contrast, and resolution. It operates primarily in China, the United States, and France. The company was founded in 2005 and is headquartered in Aix-en-Provence, France. SuperSonic Imagine SA is a subsidiary of Hologic Hub Ltd.

Eve.com

Series A in 2004
EVE offers massively multiplayer online roleplaying games. The company’s portfolio includes Eve Online, Eve Valkyrie, Gunjack, Dust 514, and Eve Universe.

CoLucid Pharmaceuticals

Series C in 2015
CoLucid Pharmaceuticals, Inc., a biotechnology company, focuses on therapies for central nervous system disorders. The company develops COL-144, a neurally acting anti-migraine agent, which is designed to treat migraine; and COL-204, a conjugated stigmine platform that produces novel chemical entities for therapy of sleep/wake disorders, chronic pain, Alzheimer's disease, and psychiatric disorders. CoLucid Pharmaceuticals was founded in 2005 and is based in Research Triangle Park, North Carolina.

EKINOPS S.A.

Series D in 2010
Ekinops is a provider of next-generation optical transport solutions for service providers and private networks. Its carrier-grade solutions leverage expertise in 10G transmission, aggregation and Forward Error Correction (FEC) to allow operators to cost-effectively increase data transport capacity over dark fiber, CWDM, DWDM, SONET/SDH, IP and SAN networks.

IDbyME

Series A in 2010
Fashion Brand selling only fully customizable item under the MoodbyMe brand.

aveni

Series E in 2013
aveni, Inc. provides metallization technologies for damascene through silicon vias, MEMS, and other electronic applications. Its portfolio includes Electrografting (eG), a wet electrochemical-based process that enables the growth of extremely high-quality thin films of various types on conducting and semiconducting surfaces; and Chemicalgrafting (cG), which is used on non-conductive substrates. The company’s eG and cG processes are implemented on hardware platforms or run on tools ranging from wet benches to automated systems. It serves semiconductor and renewable energy companies worldwide. aveni, Inc. was formerly known as Alchimer S.A. The company was founded in 2001 and is based in Massy, France.

Amoeba

Series A in 2014
Amoeba is focused on developing and commercializing green biocide water treatment chemicals. It offers BIOMEBA, a green biocide that harnesses the biocidal properties of Willaertia magna to treat the bacterial risks encountered in cooling towers.

BonitaSoft

Series C in 2013
Bonitasoft fully supports digital operations and IT modernization with Bonita, an open-source and extensible platform for automation and optimization of business processes. The Bonita platform accelerates development and production with clear separation between capabilities for visual programming and for coding. Bonita integrates with existing information systems, orchestrates heterogeneous systems, and provides deep visibility into processes across the organization.

Eptica

Venture Round in 2012
Eptica S.A. designs and develops customer relationship management (CRM) software for business-to-business (B2B) marketplaces. The company’s solutions help enterprises to develop and manage real-time relationship with clients, suppliers, and partners via the Internet. It also provides technical support, training, as well as consulting. Eptica S.A. serves banking, insurance, retail, tourism, and public institutions sectors. The company was founded in 2001 and is based in Boulogne-Billancourt, France. As of October 22, 2019, Eptica S.A. operates as a subsidiary of Enghouse Systems Limited.

Cellnovo Group SA

Series B in 2011
They believe that conventional diabetes care technology is stuck in the past, and that it has failed to put first the needs and wants of patients who have to live with the condition and the daily demands of its treatment. Those with diabetes should be put back in control, and they should live a life that is as unaffected as possible by the need to manage their condition. The experience of managing diabetes should be as positive as possible. Thoughtful and innovative design should make things easier to understand and simpler to use. With belief in these ideals, they tore up convention. When they started, they did so with a focus only on how modern technology and beautiful design would make life easier for someone managing diabetes.

Nosopharm

Venture Round in 2013
Nosopharm is a young innovative biotechnology company dedicated to anti-infective drug discovery. Nosopharm addresses the unmet medical need of the bacterial multidrug resistance to antibiotics, a very concerning issue for hospital-acquired infections. Nosopharm has set up an innovative anti-infective drug discovery platform based on the medicinal mining of the microbial biodiversity. The company has developed a unique expertise in the screening and the characterization of bioactive secondary metabolites produced by an original microbial bioresource: the bacterial genera Xenorhabdus and Photorhabdus.

Milagen

Series A in 2000
Milagen is developing and commercializing innovative products to improve the quality of life of patients suffering from cancer. For many years the company has been engaged in research and development to provide innovative proprietary products for surveillance and monitoring of major cancers. Currently, Milagen manufactures and commercializes tissue-based immunodiagnostic products as an aid to the pathologist. It also offers its product line directly to end-users, and in partnership with diagnostic companies and clinical reference laboratories. Milagen

Open-Plug

Series B in 2006
OpenPlug is a French company focused on mobile applications development tools and software for mobile phones. Its flagship product, ELIPS Studio is a cross-platform development environment for rich mobile applications. ELIPS Studio is a plugin to Adobe's Flex Builder IDE and it allows compilation of applications developed in Actionscript and MXML using Adobe's Flex framework into native code and installable application packages for iPhone, Android, Windows Mobile and Symbian devices. Other OpenPlug products include ELIPS Suite, a turnkey MMI for feature phones; and ELIPS Stack, a 3G telephony midlleware solution for MIDs.

aveni

Series C in 2007
aveni, Inc. provides metallization technologies for damascene through silicon vias, MEMS, and other electronic applications. Its portfolio includes Electrografting (eG), a wet electrochemical-based process that enables the growth of extremely high-quality thin films of various types on conducting and semiconducting surfaces; and Chemicalgrafting (cG), which is used on non-conductive substrates. The company’s eG and cG processes are implemented on hardware platforms or run on tools ranging from wet benches to automated systems. It serves semiconductor and renewable energy companies worldwide. aveni, Inc. was formerly known as Alchimer S.A. The company was founded in 2001 and is based in Massy, France.

Drug Abuse Sciences

Series A in 2001
Drug Abuse Sciences develops and commercializes therapies for the treatment of alcohol and drug addictions. It offers Naltrexone Depot, a sustained-release formulation of Naltrexone for the treatment of alcohol and opiate addictions; DAS-431 for the treatment of cocaine addiction; and Buprenorphine Depot, a sustained-release formulation of buprenorphine for the treatment of heroin and various opiate addictions. Drug Abuse Sciences is based in Menlo Park, California.

TiGenix NV

Venture Round in 2003
TiGenix NV (TiGenix) and its subsidiaries TiGenix Inc. and TC CEF LLC. is a Belgium-based biomedical company that focuses on innovative local treatments for damaged and osteoarthritic joints. The Company is exploiting the power of regenerative medicine for the development of durable treatments, validated through controlled clinical studies, for these indications. TiGenix is located in Leuven and was founded as a spin-off of the Catholic University of Leuven and the University of Ghent. TiGenix is developing a portfolio of products that addresses specific musculoskeletal problems. The lead indication among these is cartilage damage, which is a debilitating affliction severely affecting the mobility and functioning of patients. During the fiscal year ended December 31, 2009, the Company acquired Orthomimetics Ltd.

Cytoo

Series B in 2009
CYTOO focuses on innovative products for the life science research market with an emphasis in cell based assays, high content analysis and cell screening. They develop, manufacture, and distribute products that make cellular analysis robust and reliable by dramatically decreasing cell variability. There new micropattern-based products are designed to meet the needs of all clients whatever their research goals. They are open to suggestions or specific requests that can improve and spread the scope of this breakthrough in quantitative cell analysis.

Pherecydes Pharma

Series B in 2018
Pherecydes Pharma SA engages in the research and development of lytic bacteriophages for therapeutic and diagnostic applications with a focus on antibiotic resistance. It develops several banks of bacteriophages, including the collection of phages against Escherichia coli. The company was incorporated in 2006 and is based in Romainville, France.

Spine Next

Series A in 2000
Spine Next is a biotech company that manufactures and markets orthopedic spinal implant devices for spinal fusion surgeries. Spine Next is a France-based company that was founded in 1999 and the company was acquired by Abbott on October 25, 2004.

EKINOPS S.A.

Series A in 2003
Ekinops is a provider of next-generation optical transport solutions for service providers and private networks. Its carrier-grade solutions leverage expertise in 10G transmission, aggregation and Forward Error Correction (FEC) to allow operators to cost-effectively increase data transport capacity over dark fiber, CWDM, DWDM, SONET/SDH, IP and SAN networks.

Orexo

Series B in 2003
Orexo develops improved specialty pharmaceuticals and treatments for new areas of use – at a lower cost, in a shorter period of time and at a lower risk – by combining known substances with patented proprietary technologies.

Streamcore System

Series B in 2007
Streamcore is a leading provider of visibility and dynamic performance control solutions for managing interactive applications and real-time communications (VoIP, video…) delivery over the WAN. Streamcore products enable enterprises to benefit from all-in-one visibility - network, applications, VoIP, video -, real-time monitoring and advanced on-demand reporting from a single centralized management console. What makes Streamcore solutions unique is that visibility and advanced performance control are tied together and can be enabled from data centers to ensure fast deployment and cost-efficiency.

Theradiag SA

Series C in 2005
Theradiag is a France-based company which develops and markets biological diagnostic tools. The company develops and offers product panels for diagnosing autoimmune diseases, allergies, and infectious diseases.

Milagen

Series B in 2003
Milagen is developing and commercializing innovative products to improve the quality of life of patients suffering from cancer. For many years the company has been engaged in research and development to provide innovative proprietary products for surveillance and monitoring of major cancers. Currently, Milagen manufactures and commercializes tissue-based immunodiagnostic products as an aid to the pathologist. It also offers its product line directly to end-users, and in partnership with diagnostic companies and clinical reference laboratories. Milagen
At Santen, they’re innovating therapies to improve the quality of life for patients worldwide. Their single focus in ophthalmology enables us to challenge unmet needs in the field—through passionate research, successful collaboration, and clarity of commitment. With over 120 years of investigative insight, Santen remains committed to the discovery, exploration, and development of ophthalmic therapies. Now, and into the future. As a globally competitive company, Santen is often expanding to accommodate new and evolving initiatives in ophthalmic research, regulatory management, production, marketing, or distribution. Their clinical development network now spans three continents, with centers in Europe, Japan, and the United States.

Innate Pharma

Series A in 2000
Innate Pharma S.A. is a biopharmaceutical company developing first-in-class immunotherapy drug candidates for cancer and inflammatory diseases. The Company specializes in the development of novel monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Its innovative approaches have led to licensing agreements with Novo Nordisk A/S and Bristol-Myers Squibb.

Bag Tech

Series D in 2008
Bag Tech develops, designs, and manufactures a variety of bags.

Nexthink S.A.

Series A in 2007
Nexthink is a global leader in digital experience management. The company's product allows enterprises to create highly productive digital workplaces for their employees by delivering optimal end-user experience. Through a unique combination of real-time analytics, automation and employee feedback across all endpoints, Nexthink helps IT teams meet the needs of the modern digital workplace.

Pylote SAS

Venture Round in 2016
PYLOTE is an industrial company in the field of mineral and ceramic chemistry. Through its range of "PYCLEAR Tm" performance solutions, PYLOTE designs, develops and markets innovative and efficient solutions, in the form of mineral microspheres that can be integrated into many consumer products of daily life. PYLOTE is active in the pharmaceutical, cosmetics, luxury and food industry markets, helping to provide consumers with greener, cleaner and safer products.

Genocea Biosciences

Series A in 2009
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, to profile patient’s CD4+ and CD8+ T cell immune responses to potential target or antigen in that patient's tumor. It develops immuno-oncology programs, such as GEN-009, an adjuvanted neoantigen peptide vaccine candidate, which is in the phase I/IIa clinical trial; GEN-011, a neoantigen adoptive T cell therapy program; and GEN-010, a neoantigen vaccine program. Genocea Biosciences, Inc. was founded in 2006 and is based in Cambridge, Massachusetts.

Innovative Silicon

Series C in 2007
Innovative Silicon was founded to develop and commercialise Floating Body effect memory for SoC/MPU products used in diverse applications including handheld computers, games consoles, cellular communications devices, cameras. The company closed its first round of VC funding in 2003, completed its first 90nm megabit Z-RAM memory design in 2004 and its first 65nm designs in 2005. The company was founded in 2002 and is headquartered in Santa Clara, California with additional offices in Lausanne, Switzerland; and Yokohama, Japan.

Nosopharm

Venture Round in 2017
Nosopharm is a young innovative biotechnology company dedicated to anti-infective drug discovery. Nosopharm addresses the unmet medical need of the bacterial multidrug resistance to antibiotics, a very concerning issue for hospital-acquired infections. Nosopharm has set up an innovative anti-infective drug discovery platform based on the medicinal mining of the microbial biodiversity. The company has developed a unique expertise in the screening and the characterization of bioactive secondary metabolites produced by an original microbial bioresource: the bacterial genera Xenorhabdus and Photorhabdus.

Neolane

Series A in 2002
Neolane, Inc. is a conversational marketing technology provider, which develops marketing automation and cross-channel campaign management software and services for business-to-business and business-to-consumer marketers. In 2012, Neolane recorded $58 million in revenue representing 40% year-over-year growth. In 2013, Neolane was named #64 on the Forbes list of America's Most Promising companies. Neolane provides the only conversational marketing technology that empowers organizations to build and sustain one-to-one lifetime dialogues, dramatically increasing revenue and marketing efficiency. Neolane has a track record of enabling its customers to adapt to new customer engagement challenges and exploit opportunities more quickly than their competition. Neolane is used by more than 400 of the world's leading companies including Alcatel Lucent, barnesandnoble.com, Orange, Sears Canada, Sephora Europe, and Sony Music.

ERYTECH Pharma S.A.

Series C in 2011
ERYtech Pharma, set up in Lyon (France) in 2004, specializes in the encapsulation of therapeutic molecules and enzymes in red blood cells. It has achieved a major breakthrough in the fields of cancer and enzyme therapy by significantly increasing the therapeutic index of the encapsulated molecule or enzyme.

Codenvy

Series A in 2013
Codenvy is a provider of a cloud development platform designed for coding, building and testing applications.The company's cloud development environment takes the local desktop workspace, which consists of the editor, builder and tester runtimes and separates it logically from its underlying physical environment and moves it into the cloud, enabling enterprises to access workspaces that are on-demand, collaborative and constraint-free.

aveni

Series A in 2015
aveni, Inc. provides metallization technologies for damascene through silicon vias, MEMS, and other electronic applications. Its portfolio includes Electrografting (eG), a wet electrochemical-based process that enables the growth of extremely high-quality thin films of various types on conducting and semiconducting surfaces; and Chemicalgrafting (cG), which is used on non-conductive substrates. The company’s eG and cG processes are implemented on hardware platforms or run on tools ranging from wet benches to automated systems. It serves semiconductor and renewable energy companies worldwide. aveni, Inc. was formerly known as Alchimer S.A. The company was founded in 2001 and is based in Massy, France.

Convertigo S.A.

Series A in 2009
Convertigo is a privately held company recognized as a “pure player” in the enterprise Mobility market and the first software vendor to distribute its cloud based or on-premise Mobile Application Development Platform (MADP) as Open Source. Convertigo is delivering a secured and scalable disruptive all-in-one solution covering challenging backend enablement, optimized for mobility middle ware and rapid development tools for mobile applications. Convertigo team having high frequency interactions with largest customers and SI is 100% focus on developing platform and mobile oriented new features, industry solutions and practices. It’s disruptive technologies and industry standards’ integration since mobility early ages brings Convertigo to the edge of the Mobile Application Development Platform customers’ requirements. With more of 50.000 installations of its community edition, Convertigo technologies have a proven track record with secured and scalable implementations deployed in global fortune 500 companies in EMEA and North America as Carrefour, Morgan Stanley or BNP Paribas.

aveni

Series B in 2017
aveni, Inc. provides metallization technologies for damascene through silicon vias, MEMS, and other electronic applications. Its portfolio includes Electrografting (eG), a wet electrochemical-based process that enables the growth of extremely high-quality thin films of various types on conducting and semiconducting surfaces; and Chemicalgrafting (cG), which is used on non-conductive substrates. The company’s eG and cG processes are implemented on hardware platforms or run on tools ranging from wet benches to automated systems. It serves semiconductor and renewable energy companies worldwide. aveni, Inc. was formerly known as Alchimer S.A. The company was founded in 2001 and is based in Massy, France.

WALLIX GROUP SA

Venture Round in 2012
Wallix Product ( WAB Suite) gives the most effective route to security and compliance by mitigating its users’ biggest security risk – privileged access to IT – in the shortest possible time. WALLIX was founded in 2003 with a simple vision to create the most effective and complete solution to the challenges of managing privileged user access. The result of that vision is Wallix AdminBastion (WAB) Suite, a powerful combination of password, access and session management with detailed monitoring and auditing for privileged users’ activity, that now protects hundreds of customers around the world to mitigate external attacks, to control third party access, to prevent insider threat, or to meet their regulatory compliance.

NemeriX

Series B in 2005
NemeriX SA operates as a fabless semiconductor company that develops ultra-low-power, semiconductors, and software solutions for global positioning system and location-based service products. Its products include analog RF receivers, baseband, and indoor global positioning system integrates chips, as well as global positioning systems based integrated chipset. The company also offers OS support for WinCE, WinMobile, WinXP, LinuX, Symbian, and Nucleus; NeX, an extended ephemeris solution that enables mobile devices to acquire immediate positioning information in difficult garage scenarios and in harshest multi-path environments; SUPL client, which is inter-operated with several independent SUPL servers. In addition, it offers solutions to enable product integration, including evaluation boards, system software reference designs, user documentation, online support, and access to designers and global cadre of application engineers. The company’s product application areas include cellular phones, battery-powered wireless and handheld terminals, personal navigation devices, personal media players, and digital still cameras. It serves proximity-based marketing, social networking, gaming and financial authentication, navigation, tracking, and emergency markets. The company was founded in 2002 and is based in Manno, Switzerland. It has a design center in Cambridge, the United Kingdom; an applications center in Seoul, Korea; a technical center in Taipei, Taiwan; and sales offices in the United States, Europe, Taiwan, and Japan.

Pharma Omnium

Series E in 2008
Pharma Omnium is a French pharmaceutical company that markets mature drugs in various therapeutic classes. The company provides nutraceutical, dermatological, and dermo-esthetic products.

Vectalys

Venture Round in 2017
Vectalys, expert in gene delivery based on lentiviral vectors, is a private biotech company founded by Pascale Bouillé in 2005. Today, Vectalys counts 25 full-time employees exclusively dedicated to providing lentiviral vectors, cell models, molecular biology strategies and supporting your projects. Vectalys aims to help scientists worldwide understand cellular and molecular mechanisms in order to discover new drugs and therapies. Vectalys has developed a state-of-the-art proprietary technology to provide the highest quality of lentiviral vectors for the transduction of hard-to-transfect cells like primary cells, stem cells and in vivo tissues. Vectalys high quality lentiviral vectors ensure 100% transduction efficiency and non-toxic transduction on any target cells, for example to create predictive models. Because each project is unique, the Vectalys team supports you by providing custom lentiviral vectors for the right application with your gene of interest. Vectalys is also the manufacturer of highly pure ready-to-use lentiviral vectors carrying fluorescent, bioluminescent or gene editing proteins. These products are distributed worldwide. Vectalys is committed to providing solutions that save your time and support your most ambitious projects.

Hybrigenics

Series B in 2001
Hybrigenics Pharma is a bio-pharmaceutical company with a focus on research and development of new targets and therapies against cancer.Hybrigenics Pharma has stopped the development of inecalcitol, a vitamin D receptor agonist.Hybrigenics Pharma's research program investigates the action of enzymes called Deubiquitinating Enzymes (DUBs) in the recycling of onco-proteins and the potential activity of proprietary patented DUB inhibitors against various cancer indications.

Theradiag SA

Series A in 2000
Theradiag is a France-based company which develops and markets biological diagnostic tools. The company develops and offers product panels for diagnosing autoimmune diseases, allergies, and infectious diseases.

NEMOPTIC

Series D in 2006
Nemoptic, an epaper display company, designs and manufactures superior-quality bistable liquid crystal displays (LCD) modules highly suitable for consumer and professional mobile devices.

ERYTECH Pharma S.A.

Series D in 2013
ERYtech Pharma, set up in Lyon (France) in 2004, specializes in the encapsulation of therapeutic molecules and enzymes in red blood cells. It has achieved a major breakthrough in the fields of cancer and enzyme therapy by significantly increasing the therapeutic index of the encapsulated molecule or enzyme.

Nexthink S.A.

Venture Round in 2010
Nexthink is a global leader in digital experience management. The company's product allows enterprises to create highly productive digital workplaces for their employees by delivering optimal end-user experience. Through a unique combination of real-time analytics, automation and employee feedback across all endpoints, Nexthink helps IT teams meet the needs of the modern digital workplace.

Flash Therapeutics

Private Equity Round in 2018
Flash Therapeutics is a new gene therapy company developing gene and cell-based therapies by leveraging its proprietary lentiviral platform.

Pharma Omnium

Series C in 2005
Pharma Omnium is a French pharmaceutical company that markets mature drugs in various therapeutic classes. The company provides nutraceutical, dermatological, and dermo-esthetic products.

Implanet

Series A in 2007
Implanet S.A., together with its subsidiaries, designs, manufactures, and sells implants for orthopedic surgery in France, the United States, Brazil, and internationally. The company offers spinal, arthroscopy, and knee products. Its products include Jazz, Jazz Passer, Jazz Cap SP, Jazz Lock, Jazz Claw, Jazz Standalone, Jazz Frame, and Jazz Screw systems for posterior fixation. The company also offers knee prostheses, such as Madison for conventional surgical techniques. Implanet S.A. was founded in 2006 and is based in Martillac, France.

WALLIX GROUP SA

Venture Round in 2014
Wallix Product ( WAB Suite) gives the most effective route to security and compliance by mitigating its users’ biggest security risk – privileged access to IT – in the shortest possible time. WALLIX was founded in 2003 with a simple vision to create the most effective and complete solution to the challenges of managing privileged user access. The result of that vision is Wallix AdminBastion (WAB) Suite, a powerful combination of password, access and session management with detailed monitoring and auditing for privileged users’ activity, that now protects hundreds of customers around the world to mitigate external attacks, to control third party access, to prevent insider threat, or to meet their regulatory compliance.

Stantum

Venture Round in 2014
Stantum, Inc. designs and manufactures multitouch surface controllers. Its products include Lemur, which is a control surface for audio and media applications; and DEXTER, a laptop sized control surface, which is used for controlling digital audio workstations. The company’s products are used by musicians, composers, discjockies, media artists, researchers, and developers. It offers its products through distributors and retailers internationally. The company was formerly known as JazzMutant SAS and changed its name in 2007. Stantum, Inc. was founded in 2002 and is based in Bordeaux, France with a liaison office in Tokyo, Japan.

Neolane

Venture Round in 2012
Neolane, Inc. is a conversational marketing technology provider, which develops marketing automation and cross-channel campaign management software and services for business-to-business and business-to-consumer marketers. In 2012, Neolane recorded $58 million in revenue representing 40% year-over-year growth. In 2013, Neolane was named #64 on the Forbes list of America's Most Promising companies. Neolane provides the only conversational marketing technology that empowers organizations to build and sustain one-to-one lifetime dialogues, dramatically increasing revenue and marketing efficiency. Neolane has a track record of enabling its customers to adapt to new customer engagement challenges and exploit opportunities more quickly than their competition. Neolane is used by more than 400 of the world's leading companies including Alcatel Lucent, barnesandnoble.com, Orange, Sears Canada, Sephora Europe, and Sony Music.

Biolipox

Series B in 2003
Biolipox is a research-intense pharmaceutical company that develops treatments for inflammatory diseases. This includes widespread diseases such as asthma, COPD, rhinitis, and inflammatory and rheumatic pain. The company offers its users with current arachidonic acid research. Arachidonic acid is an endogenous substance that plays a central role in the development of inflammatory diseases. It is an established research area that empowers several drugs such as Aspirin, Naproxen, and Singulair. Biolipox is a Sweden-based company that was founded in 2000 and the company was acquired by Orexo on November 23, 2007.

Eve.com

Series B in 2006
EVE offers massively multiplayer online roleplaying games. The company’s portfolio includes Eve Online, Eve Valkyrie, Gunjack, Dust 514, and Eve Universe.

Alchimedics

Series A in 2007
AlchiMedics is focused on the implementation of electro-grafting technology for implantable biomedical applications. Its technology is used for fast healing post drug-eluting-stent implantation procedures. AlchiMedics was founded in 2007 and is based in Massy, France.

Nextbiotix

Series A in 2018
Exeliom is a clinical-stage biopharmaceutical company tackling the use of commensal bacteria as drugs. Their mission is to harness the therapeutic potential of gut microbiota to enable people to lead longer and healthier lives. They are committed to developing the next generation of probiotics: innovative microbial therapies. Exeliom develops a new class of medicines called Live Biotherapeutics based on their growing understanding of the central role of the microbiota in the immune system. The company was founded in 2016 and is headquartered in Dijon, France.

TxCell S.A.

Series C in 2012
TxCell, a spin off of Inserm (France's National Institute for Health and Medical Research) located in the technology park of Sophia Antipolis, near Nice in southern France, is developing cell-based immuno-therapies for the treatment of severe chronic inflammatory diseases with high medical need using its unique and proprietary technology platform based on the properties of Type 1 regulatory T lymphocytes (Tr1 cells). The company has completed enrollment of a PhI/II study in refractory Crohn's disease patients and has reported first positive results. The company plans to initiate a PhIIb study in the same patient population and bring a second product candidate into a PhI/II study in refractory rheumatoid arthritis patients.

Implanet

Series E in 2013
Implanet S.A., together with its subsidiaries, designs, manufactures, and sells implants for orthopedic surgery in France, the United States, Brazil, and internationally. The company offers spinal, arthroscopy, and knee products. Its products include Jazz, Jazz Passer, Jazz Cap SP, Jazz Lock, Jazz Claw, Jazz Standalone, Jazz Frame, and Jazz Screw systems for posterior fixation. The company also offers knee prostheses, such as Madison for conventional surgical techniques. Implanet S.A. was founded in 2006 and is based in Martillac, France.

Miliboo

Series B in 2013
Miliboo Société anonyme designs and provides furniture. The company offers sofas and armchairs, bar stools, desk and office chairs, tables, storage furniture, bathroom furniture, decor furniture, garden furniture, and table lamps, as well as furniture for children. Miliboo Société anonyme was founded in 2005 and is based in Paris, France.

Evolva Holding SA

Post in 2009
Evolva was founded in 2004 around a distinctive, proprietary, technology platform that uses synthetic biology to create innovative small molecule drugs and other compounds. In particular their platform allows the creation of chemistries that recapitulate the themes found in natural products, but without the disadvantages of those approaches.

Firalis

Series B in 2013
Firalis SAS, engages in the discovery and development of biomarker-based diagnostics. It offers inflammatory biomarkers; peripheral bio-markers for the early diagnosis of minimal vasculitis in humans; and diagnostic kits for early prediction of coxibs associated cardiovascular risks. The company’s portfolio also includes biomarkers for early kidney injuries and liver functions. In addition, it offers biomarker research and development strategy design, biomarker discovery and qualification, biomarker assay development and validation, sample testing, and integrative data analysis services. Firalis SAS was founded in 2008 and is based in Huningue, France.

Neolane

Series B in 2007
Neolane, Inc. is a conversational marketing technology provider, which develops marketing automation and cross-channel campaign management software and services for business-to-business and business-to-consumer marketers. In 2012, Neolane recorded $58 million in revenue representing 40% year-over-year growth. In 2013, Neolane was named #64 on the Forbes list of America's Most Promising companies. Neolane provides the only conversational marketing technology that empowers organizations to build and sustain one-to-one lifetime dialogues, dramatically increasing revenue and marketing efficiency. Neolane has a track record of enabling its customers to adapt to new customer engagement challenges and exploit opportunities more quickly than their competition. Neolane is used by more than 400 of the world's leading companies including Alcatel Lucent, barnesandnoble.com, Orange, Sears Canada, Sephora Europe, and Sony Music.

Pharma Omnium

Series B in 2004
Pharma Omnium is a French pharmaceutical company that markets mature drugs in various therapeutic classes. The company provides nutraceutical, dermatological, and dermo-esthetic products.
Population Genetics Technologies creates products that accelerate large-scale population studies, through the simultaneous analysis of multiple individual genomes. Their proprietary technology replaces initial sample preparation steps for next-generation DNA sequencing, overcoming cost barriers and practical constraints that limit discovery.

TxCell S.A.

Venture Round in 2014
TxCell, a spin off of Inserm (France's National Institute for Health and Medical Research) located in the technology park of Sophia Antipolis, near Nice in southern France, is developing cell-based immuno-therapies for the treatment of severe chronic inflammatory diseases with high medical need using its unique and proprietary technology platform based on the properties of Type 1 regulatory T lymphocytes (Tr1 cells). The company has completed enrollment of a PhI/II study in refractory Crohn's disease patients and has reported first positive results. The company plans to initiate a PhIIb study in the same patient population and bring a second product candidate into a PhI/II study in refractory rheumatoid arthritis patients.

Nautilus Biotech

Venture Round in 2007
Nautilus Biotech is a biotechnology company. The company has a pipeline of therapeutic proteins with improved profiles. The company's products include Belerofon, an injectable and orally available interferon alpha for use in the treatment of chronic Hepatitis C infection; and Vitatropin, an injectable and orally available human growth hormone (hGH) for use in the treatment of growth deficiencies. Nautilus Biotech S.A. sells therapeutic proteins, including interferons, hormones, growth factors, and enzymes in France and internationally. The company's protein engineering technology improves the pharmacology profile and administration route of blockbuster protein drugs. Nautilus Biotech S.A. was founded in 1999 and is based in Evry, France.

Innate Pharma

Series C in 2004
Innate Pharma S.A. is a biopharmaceutical company developing first-in-class immunotherapy drug candidates for cancer and inflammatory diseases. The Company specializes in the development of novel monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Its innovative approaches have led to licensing agreements with Novo Nordisk A/S and Bristol-Myers Squibb.

TxCell S.A.

Series B in 2008
TxCell, a spin off of Inserm (France's National Institute for Health and Medical Research) located in the technology park of Sophia Antipolis, near Nice in southern France, is developing cell-based immuno-therapies for the treatment of severe chronic inflammatory diseases with high medical need using its unique and proprietary technology platform based on the properties of Type 1 regulatory T lymphocytes (Tr1 cells). The company has completed enrollment of a PhI/II study in refractory Crohn's disease patients and has reported first positive results. The company plans to initiate a PhIIb study in the same patient population and bring a second product candidate into a PhI/II study in refractory rheumatoid arthritis patients.

Bag Tech

Series B in 2005
Bag Tech develops, designs, and manufactures a variety of bags.
Population Genetics Technologies creates products that accelerate large-scale population studies, through the simultaneous analysis of multiple individual genomes. Their proprietary technology replaces initial sample preparation steps for next-generation DNA sequencing, overcoming cost barriers and practical constraints that limit discovery.

SuperSonic Imagine SA

Series B in 2008
SuperSonic Imagine SA operates as a medical technology company. It designs, develops, and markets Aixplorer, an ultrasound system. It has developed a technology that offers practitioners and patients a breakthrough in the diagnosis and follow up of breast, prostate, and thyroid cancers, as well as liver diseases. The company’s products include Aixplorer, an ultrasound system that renders images with exceptional definition, contrast, and resolution. It operates primarily in China, the United States, and France. The company was founded in 2005 and is headquartered in Aix-en-Provence, France. SuperSonic Imagine SA is a subsidiary of Hologic Hub Ltd.

Pherecydes Pharma

Series A in 2014
Pherecydes Pharma SA engages in the research and development of lytic bacteriophages for therapeutic and diagnostic applications with a focus on antibiotic resistance. It develops several banks of bacteriophages, including the collection of phages against Escherichia coli. The company was incorporated in 2006 and is based in Romainville, France.

ERYTECH Pharma S.A.

Series B in 2010
ERYtech Pharma, set up in Lyon (France) in 2004, specializes in the encapsulation of therapeutic molecules and enzymes in red blood cells. It has achieved a major breakthrough in the fields of cancer and enzyme therapy by significantly increasing the therapeutic index of the encapsulated molecule or enzyme.

One More Company

Seed Round in 2016
Senders™ is a contextual intelligence email service offered by One More Company, Inc, the company behind Trackbuster™, which offered the same email untracking features now available as part of Senders. Senders is the latest product from One More Company. It functions like Caller ID for email by providing the recipient more information about the sender right in the email, so it works everywhere, regardless of app, platform, and device. Senders™ is a patent-pending service designed and securely hosted in the US. They are focused on enhancing the email experience for individuals and businesses by helping users filter the messaging signal from the noise and providing relevant information on the fly, in an open way. They provide simple, intuitive services around messaging and the cloud. They are driven by a digital ethics based on consumer control, privacy, and transparency. Their users are their customers and their interests are paramount. Their business model is not based on selling ads, or collecting and selling data. At One More Company, Inc., creating a positive consumer experience is their highest priority, and their raison d’être. Their products are designed to make life easier. They can’t do that without ensuring user privacy and the security of personal information. So, they think about privacy and security from the beginning, and throughout the product design process; in other words, privacy by design. One More Company, Inc is a U.S. corporation founded by seasoned executives with decades of experience in Silicon Valley, at places like Google, Facebook, Twitter, and IBM. It has offices in New York and Paris. Senders™ is a patent-pending service designed and securely hosted in the USA.

Genocea Biosciences

Series B in 2009
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, to profile patient’s CD4+ and CD8+ T cell immune responses to potential target or antigen in that patient's tumor. It develops immuno-oncology programs, such as GEN-009, an adjuvanted neoantigen peptide vaccine candidate, which is in the phase I/IIa clinical trial; GEN-011, a neoantigen adoptive T cell therapy program; and GEN-010, a neoantigen vaccine program. Genocea Biosciences, Inc. was founded in 2006 and is based in Cambridge, Massachusetts.
Population Genetics Technologies creates products that accelerate large-scale population studies, through the simultaneous analysis of multiple individual genomes. Their proprietary technology replaces initial sample preparation steps for next-generation DNA sequencing, overcoming cost barriers and practical constraints that limit discovery.

aveni

Series B in 2005
aveni, Inc. provides metallization technologies for damascene through silicon vias, MEMS, and other electronic applications. Its portfolio includes Electrografting (eG), a wet electrochemical-based process that enables the growth of extremely high-quality thin films of various types on conducting and semiconducting surfaces; and Chemicalgrafting (cG), which is used on non-conductive substrates. The company’s eG and cG processes are implemented on hardware platforms or run on tools ranging from wet benches to automated systems. It serves semiconductor and renewable energy companies worldwide. aveni, Inc. was formerly known as Alchimer S.A. The company was founded in 2001 and is based in Massy, France.

NGI

Series A in 2007
TcLand Expression is a fully integrated company displaying high expertise in all stages of biomarker development: R&D, bioinformatics & biostatistics, clinical & regulatory , market access and production. TcLand Expression is a pioneer and European leader in personalized medicine in immunology (transplantation and auto-immune disorders) with a rich pipeline of biomarkers in development.
Population Genetics Technologies creates products that accelerate large-scale population studies, through the simultaneous analysis of multiple individual genomes. Their proprietary technology replaces initial sample preparation steps for next-generation DNA sequencing, overcoming cost barriers and practical constraints that limit discovery.

ERYTECH Pharma S.A.

Venture Round in 2006
ERYtech Pharma, set up in Lyon (France) in 2004, specializes in the encapsulation of therapeutic molecules and enzymes in red blood cells. It has achieved a major breakthrough in the fields of cancer and enzyme therapy by significantly increasing the therapeutic index of the encapsulated molecule or enzyme.

WALLIX GROUP SA

Series A in 2011
Wallix Product ( WAB Suite) gives the most effective route to security and compliance by mitigating its users’ biggest security risk – privileged access to IT – in the shortest possible time. WALLIX was founded in 2003 with a simple vision to create the most effective and complete solution to the challenges of managing privileged user access. The result of that vision is Wallix AdminBastion (WAB) Suite, a powerful combination of password, access and session management with detailed monitoring and auditing for privileged users’ activity, that now protects hundreds of customers around the world to mitigate external attacks, to control third party access, to prevent insider threat, or to meet their regulatory compliance.

Nautilus Biotech

Venture Round in 2005
Nautilus Biotech is a biotechnology company. The company has a pipeline of therapeutic proteins with improved profiles. The company's products include Belerofon, an injectable and orally available interferon alpha for use in the treatment of chronic Hepatitis C infection; and Vitatropin, an injectable and orally available human growth hormone (hGH) for use in the treatment of growth deficiencies. Nautilus Biotech S.A. sells therapeutic proteins, including interferons, hormones, growth factors, and enzymes in France and internationally. The company's protein engineering technology improves the pharmacology profile and administration route of blockbuster protein drugs. Nautilus Biotech S.A. was founded in 1999 and is based in Evry, France.

Gamida Cell Ltd.

Series A in 2000
Gamida Cell is dedicated to making a significant difference in the clinical practice of modern medicine by first creating, then tapping the regenerative power of therapeutic stem cells. Gamida Cell is a leader in the development of stem cell therapy technologies and products. The therapies are based on expanded populations of cord blood stem cells, for the treatment of illnesses with significant unmet clinical needs such as blood cancers, autoimmune and metabolic diseases as well as neutropenia.

Drug Abuse Sciences

Series B in 2003
Drug Abuse Sciences develops and commercializes therapies for the treatment of alcohol and drug addictions. It offers Naltrexone Depot, a sustained-release formulation of Naltrexone for the treatment of alcohol and opiate addictions; DAS-431 for the treatment of cocaine addiction; and Buprenorphine Depot, a sustained-release formulation of buprenorphine for the treatment of heroin and various opiate addictions. Drug Abuse Sciences is based in Menlo Park, California.

Cytoo

Series C in 2011
CYTOO focuses on innovative products for the life science research market with an emphasis in cell based assays, high content analysis and cell screening. They develop, manufacture, and distribute products that make cellular analysis robust and reliable by dramatically decreasing cell variability. There new micropattern-based products are designed to meet the needs of all clients whatever their research goals. They are open to suggestions or specific requests that can improve and spread the scope of this breakthrough in quantitative cell analysis.

Miliboo

Series A in 2011
Miliboo Société anonyme designs and provides furniture. The company offers sofas and armchairs, bar stools, desk and office chairs, tables, storage furniture, bathroom furniture, decor furniture, garden furniture, and table lamps, as well as furniture for children. Miliboo Société anonyme was founded in 2005 and is based in Paris, France.

BonitaSoft

Series B in 2011
Bonitasoft fully supports digital operations and IT modernization with Bonita, an open-source and extensible platform for automation and optimization of business processes. The Bonita platform accelerates development and production with clear separation between capabilities for visual programming and for coding. Bonita integrates with existing information systems, orchestrates heterogeneous systems, and provides deep visibility into processes across the organization.

Gamida Cell Ltd.

Series C in 2005
Gamida Cell is dedicated to making a significant difference in the clinical practice of modern medicine by first creating, then tapping the regenerative power of therapeutic stem cells. Gamida Cell is a leader in the development of stem cell therapy technologies and products. The therapies are based on expanded populations of cord blood stem cells, for the treatment of illnesses with significant unmet clinical needs such as blood cancers, autoimmune and metabolic diseases as well as neutropenia.

SuperSonic Imagine SA

Private Equity Round in 2013
SuperSonic Imagine SA operates as a medical technology company. It designs, develops, and markets Aixplorer, an ultrasound system. It has developed a technology that offers practitioners and patients a breakthrough in the diagnosis and follow up of breast, prostate, and thyroid cancers, as well as liver diseases. The company’s products include Aixplorer, an ultrasound system that renders images with exceptional definition, contrast, and resolution. It operates primarily in China, the United States, and France. The company was founded in 2005 and is headquartered in Aix-en-Provence, France. SuperSonic Imagine SA is a subsidiary of Hologic Hub Ltd.

NemeriX

Series C in 2007
NemeriX SA operates as a fabless semiconductor company that develops ultra-low-power, semiconductors, and software solutions for global positioning system and location-based service products. Its products include analog RF receivers, baseband, and indoor global positioning system integrates chips, as well as global positioning systems based integrated chipset. The company also offers OS support for WinCE, WinMobile, WinXP, LinuX, Symbian, and Nucleus; NeX, an extended ephemeris solution that enables mobile devices to acquire immediate positioning information in difficult garage scenarios and in harshest multi-path environments; SUPL client, which is inter-operated with several independent SUPL servers. In addition, it offers solutions to enable product integration, including evaluation boards, system software reference designs, user documentation, online support, and access to designers and global cadre of application engineers. The company’s product application areas include cellular phones, battery-powered wireless and handheld terminals, personal navigation devices, personal media players, and digital still cameras. It serves proximity-based marketing, social networking, gaming and financial authentication, navigation, tracking, and emergency markets. The company was founded in 2002 and is based in Manno, Switzerland. It has a design center in Cambridge, the United Kingdom; an applications center in Seoul, Korea; a technical center in Taipei, Taiwan; and sales offices in the United States, Europe, Taiwan, and Japan.

Isocell

Series A in 2011
GliSODin Skin Nutrients is a professional medical line of nutricosmetics focused on optimal internal support. It provides the skin with essential nutrients and functions to protect it from the effects of oxidative stress. GliSODin Skin Nutrients was founded in 2008 and is based in Paris, France.

Implanet

Series C in 2010
Implanet S.A., together with its subsidiaries, designs, manufactures, and sells implants for orthopedic surgery in France, the United States, Brazil, and internationally. The company offers spinal, arthroscopy, and knee products. Its products include Jazz, Jazz Passer, Jazz Cap SP, Jazz Lock, Jazz Claw, Jazz Standalone, Jazz Frame, and Jazz Screw systems for posterior fixation. The company also offers knee prostheses, such as Madison for conventional surgical techniques. Implanet S.A. was founded in 2006 and is based in Martillac, France.

Availpro SAS

Series B in 2011
Availpro SAS develops and delivers e-booking software solutions that allow hotels to increase their occupancy and revenue. It offers Smart Booking Engine, a solution to increase sales on website; Facebook Booking Engine, a solution to boost hotel’s social sales and promote special offers; Mobile Booking Engine, a solution to make mobile sales a reality; Smart Channel Manager, a solution to manage availability rooms and rates with a single planner; and PMS/CRS connectivity, a solution to convert availability into bookings. The company also provides GDS connectivity, a solution to sell rooms directly through travel agencies; RateScreener/Parity Checker, a solution to analyze and compare competitors’ rates; NextRate, a solution to optimize and sell at the right price; Guest Reviews, a solution to improve guest satisfaction; and Sentinel, a solution to monitor and analyze hotel’s online reputation. It serves independent hotels, hotel chains and hotel groups, and aparthotels. Availpro SAS was formerly known as Siriona S.A. The company was founded in 2001 and is based in Paris, France with sales offices in Europe. As of April 5, 2017, Availpro SAS operates as a subsidiary of Accor SA.

Domain Therapeutics SA

Venture Round in 2012
Domain Therapeutics is a biopharmaceutical company located in Strasbourg, France, dedicated to the discovery and early development of small molecules targeting G-coupled Protein Receptors (GPCRs), one of the best classes of drug targets. Domain Therapeutics is using its innovative and proprietary technology platform DTect-Allâ„¢ to identify orthosteric and allosteric ligands of GPCRs, including the so called Silent Allosteric Modulators (SAMs) that represent a unique source of compounds that cannot be discovered by standard technologies. DTect-Allâ„¢ is able to address difficult GPCRs such as orphan and peptidic GPCRs.

Gamida Cell Ltd.

Series E in 2012
Gamida Cell is dedicated to making a significant difference in the clinical practice of modern medicine by first creating, then tapping the regenerative power of therapeutic stem cells. Gamida Cell is a leader in the development of stem cell therapy technologies and products. The therapies are based on expanded populations of cord blood stem cells, for the treatment of illnesses with significant unmet clinical needs such as blood cancers, autoimmune and metabolic diseases as well as neutropenia.

Fab'entech

Series A in 2014
Founded in 2009 in Lyon, France and located and member of LyonBiopôle cluster, Fab’entech is a biopharmaceutical company which develops and commercializes a range of innovative passive immunotherapeutic solutions based on specific polyclonal immunoglobulins [F(ab’)₂] in the field of emerging infectious diseases, as well as for certain drug intoxications.